These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

740 related articles for article (PubMed ID: 27783996)

  • 1. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
    Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
    Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
    Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J
    Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A transgenic zebrafish model expressing KIT-D816V recapitulates features of aggressive systemic mastocytosis.
    Balci TB; Prykhozhij SV; Teh EM; Da'as SI; McBride E; Liwski R; Chute IC; Leger D; Lewis SM; Berman JN
    Br J Haematol; 2014 Oct; 167(1):48-61. PubMed ID: 24989799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.
    Schneeweiss M; Peter B; Bibi S; Eisenwort G; Smiljkovic D; Blatt K; Jawhar M; Berger D; Stefanzl G; Herndlhofer S; Greiner G; Hoermann G; Hadzijusufovic E; Gleixner KV; Bettelheim P; Geissler K; Sperr WR; Reiter A; Arock M; Valent P
    Haematologica; 2018 May; 103(5):799-809. PubMed ID: 29439183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
    Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
    Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection.
    Saleh R; Wedeh G; Herrmann H; Bibi S; Cerny-Reiterer S; Sadovnik I; Blatt K; Hadzijusufovic E; Jeanningros S; Blanc C; Legarff-Tavernier M; Chapiro E; Nguyen-Khac F; Subra F; Bonnemye P; Dubreuil P; Desplat V; Merle-Béral H; Willmann M; Rülicke T; Valent P; Arock M
    Blood; 2014 Jul; 124(1):111-20. PubMed ID: 24677542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
    Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
    Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.
    Jin Y; Ding K; Wang D; Shen M; Pan J
    Cancer Lett; 2014 Oct; 353(1):115-23. PubMed ID: 25088577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis.
    Bandara G; Falduto GH; Luker A; Bai Y; Pfeiffer A; Lack J; Metcalfe DD; Olivera A
    Front Immunol; 2023; 14():1078958. PubMed ID: 37025992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).
    Peter B; Hadzijusufovic E; Blatt K; Gleixner KV; Pickl WF; Thaiwong T; Yuzbasiyan-Gurkan V; Willmann M; Valent P
    Exp Hematol; 2010 Sep; 38(9):782-91. PubMed ID: 20685234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
    Shomali W; Gotlib J
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
    Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis.
    Hoermann G; Cerny-Reiterer S; Perné A; Klauser M; Hoetzenecker K; Klein K; Müllauer L; Gröger M; Nijman SM; Klepetko W; Valent P; Mayerhofer M
    Am J Pathol; 2011 May; 178(5):2344-56. PubMed ID: 21457934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells.
    Chan EC; Bai Y; Bandara G; Simakova O; Brittain E; Scott L; Dyer KD; Klion AD; Maric I; Gilfillan AM; Metcalfe DD; Wilson TM
    Exp Hematol; 2013 Oct; 41(10):870-881.e2. PubMed ID: 23743299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications.
    Jara-Acevedo M; Teodosio C; Sanchez-Muñoz L; Álvarez-Twose I; Mayado A; Caldas C; Matito A; Morgado JM; Muñoz-González JI; Escribano L; Garcia-Montero AC; Orfao A
    Mod Pathol; 2015 Aug; 28(8):1138-49. PubMed ID: 26067933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.
    Jin B; Ding K; Pan J
    Mol Cancer Ther; 2014 May; 13(5):1217-30. PubMed ID: 24552773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
    Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
    Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
    Baird JH; Gotlib J
    Curr Hematol Malig Rep; 2018 Oct; 13(5):407-416. PubMed ID: 30155614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kit Mutations: New Insights and Diagnostic Value.
    Falchi L; Verstovsek S
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
    Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
    Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.